"10.1371_journal.pone.0035416","plos one","2012-05-09T00:00:00Z","Julianna Lisziewicz; Nyasha Bakare; Sandra A Calarota; Dénes Bánhegyi; János Szlávik; Eszter Újhelyi; Enikő R Tőke; Levente Molnár; Zsolt Lisziewicz; Brigitte Autran; Franco Lori","Genetic Immunity, Budapest, Hungary and Genetic Immunity Inc, Mclean, Virginia, United States of America; The Research Institute for Genetic and Human Therapy, Cambridge, Massachusetts, United States of America; Szent László Hospital, Budapest, Hungary; Laboratoire d Immunologie Cellulaire, Centre Hospitalier Universitaire Pitié-Salpétrière, Paris, France","Conceived and designed the experiments: JL FL NB. Performed the experiments: SAC DB JS EU BA. Analyzed the data: LM ZL JL FL NB BA. Contributed reagents/materials/analysis tools: BA EU SAC. Wrote the paper: JL ERT.","Study sponsored by Commercial funder Genetic Immunity, LLC; JL, NB, ZL and FL are employees of or hold shares in Genetic Immunity Inc. There are several patent applications to protect DermaVir product and technology - JL, FL, ET from Genetic Immunity could benefit. DermaVir is a immunotherapeutic product candidate in development by Genetic Immunity. There are no other patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2012","05","Julianna Lisziewicz","JL",11,TRUE,3,5,6,2,TRUE,TRUE,TRUE,1,"6",FALSE
